Company Profile
Disc Medicine Stock Price, News & Analysis
- Ticker:
- IRON
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
77.44 USD (-1.86%)
Close
Last updated: August 6, 2026
2.6B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IRON closed down 1.86% at $77.44. No new same-company headline was identified in the current news window.
Company overview
Hematology Drug Development
Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease.
Bitopertin in EPP
Bitopertin is being evaluated in the Phase 3 APOLLO trial for erythropoietic protoporphyria, a disorder caused by accumulation of phototoxic protoporphyrin. The program has completed enrollment and is intended to support a response to an earlier FDA complete response letter.
DISC-0974 for Anemia
DISC-0974 is an investigational anti-hemojuvelin therapy designed to suppress hepcidin and improve iron availability. It is being studied in the Phase 2 RALLY-MF trial for anemia of myelofibrosis and in a separate Phase 2 study for anemia associated with inflammatory bowel disease.
DISC-3405
DISC-3405 is a monoclonal antibody targeting transferrin receptor 1. The candidate is in Phase 2 development for polycythemia vera and Phase 1b development for sickle cell disease, extending Disc’s approach to disorders of red-cell production and function.
Future catalysts
Updated RALLY-MF Phase 2 data for DISC-0974 to be presented at ASCO in June 2026.
Topline results from the Phase 3 APOLLO trial of bitopertin expected in the fourth quarter of 2026.
Topline RALLY-MF results and an end-of-Phase 2 FDA meeting expected by year-end 2026.
Initial data from DISC-3405 studies in polycythemia vera and sickle cell disease expected in the fourth quarter of 2026.
Response to the bitopertin complete response letter following APOLLO, with an FDA decision expected by mid-2027.
Initial Phase 2 data for DISC-0974 in inflammatory bowel disease expected in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
Source: Disc Medicine
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Disc Medicine (IRON)?
Disc Medicine (IRON) most recently closed at 77.44 USD, a -1.86% move versus the previous session.
What is the market cap of Disc Medicine (IRON)?
Disc Medicine currently has a market capitalization of 2.6B USD on BioPharmSignal.
What does Disc Medicine do?
Hematology Drug Development Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease. Bitopertin in EPP Bitopertin is being evaluated in the Phase 3 APOLLO trial for...
On which exchange is IRON stock listed?
Disc Medicine (IRON) is associated with NASDAQ, United States, Biopharma.
What is DISC-0974?
Updated RALLY-MF Phase 2 data for DISC-0974 to be presented at ASCO in June 2026.
Which conditions is Disc Medicine targeting with DISC-0974?
Disc Medicine is associated with hematology based on its company overview and current catalyst commentary.
How does Disc Medicine describe recent progress with DISC-0974?
Updated RALLY-MF Phase 2 data for DISC-0974 to be presented at ASCO in June 2026.
What is RALLY-MF?
It is being studied in the Phase 2 RALLY-MF trial for anemia of myelofibrosis and in a separate Phase 2 study for anemia associated with inflammatory bowel disease.